Active	Status	Sponsor type	Region	Phase	Filter
8 Active 2 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Chen, Dedian
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer	Active, not recruiting	3	274	RoW	BPI-16350, placebo, Fulvestrant	Betta Pharmaceuticals Co., Ltd.	Breast Cancer	12/23	07/25
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer	Recruiting	3	350	RoW	GB491 combined with Letrozole, Placebo combined with Letrozole	Genor Biopharma Co., Ltd.	Breast Cancer	01/26	01/27
Li, Zhenhui
No trials found